To review the clinical evidence for pharmacological strategies targeting the incretin axis in preventing type 2 diabetes in individuals with obesity and prediabetes, emphasizing its significance.
Key Findings:
Liraglutide reduced diabetes incidence by 79% in prediabetic patients, a clinically significant reduction.
Semaglutide showed consistent benefits in multiple trials, including significant reversion to normoglycemia, with clinical implications.
Tirzepatide demonstrated unprecedented weight loss and reduction in diabetes onset, outperforming semaglutide in real-world data, highlighting its clinical relevance.
Interpretation:
Pharmacotherapy targeting the incretin axis is crucial in modifying the natural history of prediabetes and preventing type 2 diabetes in obese patients, with a focus on integration with lifestyle changes.
Limitations:
Liraglutide has a smaller weight loss effect compared to semaglutide and tirzepatide, and potential side effects should be considered.
The mechanisms of action for diabetes prevention are not fully understood, and long-term safety concerns remain.
Conclusion:
Advancements in obesity pharmacotherapy, particularly GLP-1 and dual GLP-1/GIP receptor agonists, are making diabetes prevention a realistic goal, emphasizing the need for a comprehensive approach.
